Study to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes
Open-Label, Non-Randomized, Single-Arm, Multicenter Pilot Clinical Trial to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes
FAITH-T1D/1, exploratory, Phase I, open-label, non-randomized, single-arm, multicenter clinical trial designed to evaluate the dose-dependent effects of tirzepatide on gastric emptying in adults with type 1 diabetes (T1D) and overweight or obesity.
The study will investigate tirzepatide administered once weekly as an adjunct to participants' usual insulin therapy delivered through automated insulin delivery (AID) systems. Tirzepatide will be administered subcutaneously, with gradual dose escalation from 2.5 mg up to 15 mg at four-week intervals, according to clinical tolerability and the protocol-defined dosing schedule. Its use in this population is off-label.
The study follows a longitudinal, within-subject design in which each participant serves as their own control. Gastric emptying will be assessed by gastric emptying scintigraphy using a standardized solid meal at baseline and at weeks 4, 8, 16 and 24. The primary objective is to characterize changes in gastric emptying in relation to tirzepatide dose. Secondary and exploratory objectives include evaluating metabolic and glycemic parameters, gastrointestinal symptoms, postprandial glucagon, lipidomic and metabolomic profiles, and the safety and tolerability of treatment. Continuous glucose monitoring and AID system data will also be reviewed throughout the study.
The target is 12 evaluable participants, with a maximum of 14 participants allowed to account for early withdrawals before an evaluable post-baseline assessment. The study includes a screening period, approximately 24 weeks of treatment and follow-up assessments through week 30.
Safety assessments will include treatment-emergent adverse events, gastrointestinal symptoms, hypoglycemia and diabetic ketoacidosis, as well as monitoring of tolerability during dose escalation. An independent Data and Safety Monitoring Committee is planned in accordance with the protocol.
The trial will be conducted at two Spanish hospital centers: Hospital Universitario Ramón y Cajal and Hospital Universitari i Politècnic La Fe. The study is exploratory and mechanistic; it is intended to characterize pharmacodynamic effects, estimate within-subject changes and inform the design of future confirmatory studies, rather than establish definitive clinical efficacy.
Tutkimuksen yleiskatsaus
Tila
Tila
Ehdot
Ehdot
Interventio / Hoito
Interventio / Hoito
Opintotyyppi
Opintotyyppi
Ilmoittautuminen (Arvioitu)
Ilmoittautuminen
Vaihe
Vaihe
- Vaihe 1
Yhteystiedot ja paikat
Opiskelupaikat
-
-
Madrid
-
Madrid, Madrid, Espanja, 28034
- Rekrytointi
- Hospital Universitario Ramón y Cajal
-
Ottaa yhteyttä:
- Maria Lia Nattero Principal investigator, MD
- Puhelinnumero: +34 913369029
- Sähköposti: marialia.nattero@salud.madrid.org
-
-
Osallistumiskriteerit
Kelpoisuusvaatimukset
Kelpoisuusvaatimukset
Opintokelpoiset iät
Hyväksyy terveitä vapaaehtoisia
Sukupuolet, jotka voivat opiskella
Kuvaus
Inclusion Criteria:
- Written informed consent: Participants must have received information about the study design, objectives, and potential risks and must provide written informed consent to participate.
- Ability to comply with study procedures: Ability and willingness to understand the study, comply with the required procedures, and attend all scheduled visits.
- Age and diagnosis: Age ≥18 years and an established diagnosis of type 1 diabetes mellitus (T1D) for at least 1 year.
- Stable automated insulin delivery (AID) treatment: Stable treatment with an AID system for at least 90 days before the baseline visit (Visit 0), with a commitment to maintain the same mode of insulin delivery and insulin throughout the study.
- Baseline HbA1c: HbA1c between 6.3% and 10.5% at baseline.
- Body mass index and weight stability: BMI ≥25 kg/m², with stable body weight (variation ≤5 kg) during at least the 90 days before inclusion.
- Contraception requirements: Participants with reproductive potential must agree to use effective contraception throughout the study and for at least 6 months after the end of the study. The protocol specifies a highly effective contraceptive method plus a barrier method for participants with reproductive potential.
Exclusion Criteria:
Glycemic control and diabetes
-
Two or more episodes requiring hospitalization for poor glycemic control (hyperglycemia or diabetic ketoacidosis [DKA]) during the 180 days before the baseline visit.
-
One or more episodes of severe hypoglycemia requiring assistance from another person during the 90 days before baseline.
Diabetes complications
-
Active proliferative diabetic retinopathy, or a history of ophthalmologic treatment (photocoagulation, intravitreal injections, or vitrectomy) during the previous 6 months, or anticipated need for such treatment during the 6 months after inclusion.
Recent cardiovascular disease
-
Cardiovascular events during the 60 days before baseline, including:
- Acute myocardial infarction.
- Stroke.
- Coronary revascularization.
- Hospitalization for unstable angina.
- Heart failure. Gastrointestinal disorders and motility
-
Clinically significant gastrointestinal disorders, including diabetic gastroparesis.
-
Previous bariatric surgery.
-
Chronic use of medications that directly affect gastrointestinal motilityRenal function
-
Estimated glomerular filtration rate (eGFR) below 15 mL/min/1.73 m² at baseline.
Neoplasms
-
Active malignancy or malignancy in remission for less than 5 years.
-
Personal or first-degree family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 (MEN2).
Psychiatric disorders
-
Severe or unstable psychiatric disorders, including uncontrolled major depression, schizophrenia, bipolar disorder, or other severe psychiatric conditions, or severe mood or anxiety disorders during the previous 2 years.
Concomitant medications
-
Systemic glucocorticoid use for more than 14 days during the 90 days before baseline, excluding replacement therapy.
-
Use of weight-loss medications or glucose-lowering medications other than insulin during the 90 days before baseline.
Hypersensitivity
-
Hypersensitivity to tirzepatide or any of its excipients.
Opintosuunnitelma
Miten tutkimus on suunniteltu?
Suunnittelun yksityiskohdat
- Ensisijainen käyttötarkoitus: Terveyspalvelututkimus
- Jako: Ei käytössä
- Inventiomalli: Yksittäinen ryhmätehtävä
- Naamiointi: Ei mitään (avoin tarra)
Aseiden lukumäärä
Aseet ja interventiot
Osallistujaryhmä / ArmOsallistujaryhmä / Arm |
Interventio / HoitoInterventio / Hoito |
|---|---|
|
Kokeellinen: Tirzepatide
Tirzepatide with dose escalation from 2.5 mg to 15 mg. |
Tirzepatide with dose escalation from 2.5 mg to 15 mg. |
Mitä tutkimuksessa mitataan?
Ensisijaiset tulostoimenpiteet
Ensisijaiset tulostoimenpiteet
Tulosmittaus |
Aikaikkuna |
|---|---|
|
To characterize the dose-dependent effect of tirzepatide (2.5-15 mg) on gastric emptying (GE) in adults with type 1 diabetes (T1D) and overweight/obesity, assessed as the within-subject change from baseline using gastric emptying scintigraphy (GES).
Aikaikkuna: Baseline (Week 0) and Weeks 4, 8, 16, and 24.
|
Baseline (Week 0) and Weeks 4, 8, 16, and 24.
|
Toissijaiset tulostoimenpiteet
Toissijaiset tulostoimenpiteet
Tulosmittaus |
Aikaikkuna |
|---|---|
|
Change from baseline in gastric emptying half-time (t½)
Aikaikkuna: Baseline (Week 0) and Weeks 4, 8, 16, and 24
|
Baseline (Week 0) and Weeks 4, 8, 16, and 24
|
|
Change from baseline in the area under the gastric retention curve over 0-4 hours (AUC₀-₄h).
Aikaikkuna: Baseline (Week 0) and Weeks 4, 8, 16, and 24
|
Baseline (Week 0) and Weeks 4, 8, 16, and 24
|
|
Change from baseline in gastric retention at 2 hours (%GR-2h).
Aikaikkuna: Baseline (Week 0) and Weeks 4, 8, 16, and 24
|
Baseline (Week 0) and Weeks 4, 8, 16, and 24
|
|
Change from baseline in gastric retention at 4 hours (%GR-4h).
Aikaikkuna: Baseline (Week 0) and Weeks 4, 8, 16, and 24
|
Baseline (Week 0) and Weeks 4, 8, 16, and 24
|
|
Changes in continuous glucose monitoring (CGM) metrics during tirzepatide dose escalation including time in tight range (70-140 mg/dL)
Aikaikkuna: During the 24-week treatment period, using CGM data from the final 7 days of each dose-titration phase
|
During the 24-week treatment period, using CGM data from the final 7 days of each dose-titration phase
|
|
Changes in continuous glucose monitoring (CGM) metrics during tirzepatide dose escalation including time in range (TIR, 70-180 mg/dL)
Aikaikkuna: During the 24-week treatment period, using CGM data from the final 7 days of each dose-titration phase
|
During the 24-week treatment period, using CGM data from the final 7 days of each dose-titration phase
|
|
Changes in continuous glucose monitoring (CGM) metrics during tirzepatide dose escalation including time in hypoglycemia
Aikaikkuna: During the 24-week treatment period, using CGM data from the final 7 days of each dose-titration phase
|
During the 24-week treatment period, using CGM data from the final 7 days of each dose-titration phase
|
|
Changes in continuous glucose monitoring (CGM) metrics during tirzepatide dose escalation including time in hyperglycemia
Aikaikkuna: During the 24-week treatment period, using CGM data from the final 7 days of each dose-titration phase
|
During the 24-week treatment period, using CGM data from the final 7 days of each dose-titration phase
|
|
Changes in continuous glucose monitoring (CGM) metrics during tirzepatide dose escalation including glycemic variability.
Aikaikkuna: During the 24-week treatment period, using CGM data from the final 7 days of each dose-titration phase
|
During the 24-week treatment period, using CGM data from the final 7 days of each dose-titration phase
|
|
Correlation between dose-dependent delays in gastric emptying and improvements in postprandial glucose excursions (TIR, 70-180 mg/dL).
Aikaikkuna: Baseline (Week 0) and Weeks 4, 8, 16, and 24; postprandial glucose assessed over the 6 hours following the standardized test meal
|
Baseline (Week 0) and Weeks 4, 8, 16, and 24; postprandial glucose assessed over the 6 hours following the standardized test meal
|
|
Changes in insulin requirements, including total daily insulin dose
Aikaikkuna: Baseline (Week 0) and during the 24-week treatment period, with assessments at Weeks 4, 8, 12, 16, 20, and 24.
|
Baseline (Week 0) and during the 24-week treatment period, with assessments at Weeks 4, 8, 12, 16, 20, and 24.
|
|
Changes in insulin requirements, including the ratio of prandial to basal insulin dose.
Aikaikkuna: Baseline (Week 0) and during the 24-week treatment period, with assessments at Weeks 4, 8, 12, 16, 20, and 24.
|
Baseline (Week 0) and during the 24-week treatment period, with assessments at Weeks 4, 8, 12, 16, 20, and 24.
|
|
Change in HbA1c from baseline to the end of the study.
Aikaikkuna: Baseline (Week 0) and Week 30 (end-of-study visit).
|
Baseline (Week 0) and Week 30 (end-of-study visit).
|
|
Changes in body weight (kg)
Aikaikkuna: Baseline (Week 0), Weeks 4, 8, 12, 16, 20, and 24, and Week 30 (end-of-study visit).
|
Baseline (Week 0), Weeks 4, 8, 12, 16, 20, and 24, and Week 30 (end-of-study visit).
|
|
Changes in body mass index (kg/m²)
Aikaikkuna: Baseline (Week 0), Weeks 4, 8, 12, 16, 20, and 24, and Week 30 (end-of-study visit).
|
Baseline (Week 0), Weeks 4, 8, 12, 16, 20, and 24, and Week 30 (end-of-study visit).
|
|
Changes in waist-to-hip ratio (cm)
Aikaikkuna: Baseline (Week 0), Weeks 4, 8, 12, 16, 20, and 24, and Week 30 (end-of-study visit).
|
Baseline (Week 0), Weeks 4, 8, 12, 16, 20, and 24, and Week 30 (end-of-study visit).
|
|
Changes in percentage of body fat
Aikaikkuna: Baseline (Week 0), Weeks 4, 8, 12, 16, 20, and 24, and Week 30 (end-of-study visit).
|
Baseline (Week 0), Weeks 4, 8, 12, 16, 20, and 24, and Week 30 (end-of-study visit).
|
|
Changes from baseline in postprandial glucagon concentrations
Aikaikkuna: Baseline (Week 0) and Weeks 4, 8, 16, and 24; blood samples collected at 0, 30, 60, 120, 180, and 240 minutes during each gastric emptying scintigraphy assessment
|
Baseline (Week 0) and Weeks 4, 8, 16, and 24; blood samples collected at 0, 30, 60, 120, 180, and 240 minutes during each gastric emptying scintigraphy assessment
|
|
Changes from baseline in postprandial lipidomic profiles (Lipoprotein Cholesterol (mg/dL))
Aikaikkuna: Baseline (Week 0) and Weeks 4, 8, 16, and 24; blood samples collected at 0, 30, 60, 120, 180, and 240 minutes during each gastric emptying scintigraphy assessment
|
Baseline (Week 0) and Weeks 4, 8, 16, and 24; blood samples collected at 0, 30, 60, 120, 180, and 240 minutes during each gastric emptying scintigraphy assessment
|
|
Changes from baseline in postprandial lipidomic profiles (Triglycerides (mg/dL))
Aikaikkuna: Baseline (Week 0) and Weeks 4, 8, 16, and 24; blood samples collected at 0, 30, 60, 120, 180, and 240 minutes during each gastric emptying scintigraphy assessment
|
Baseline (Week 0) and Weeks 4, 8, 16, and 24; blood samples collected at 0, 30, 60, 120, 180, and 240 minutes during each gastric emptying scintigraphy assessment
|
|
Changes from baseline in postprandial lipidomic profiles (Particle Number (nmol/L))
Aikaikkuna: Baseline (Week 0) and Weeks 4, 8, 16, and 24; blood samples collected at 0, 30, 60, 120, 180, and 240 minutes during each gastric emptying scintigraphy assessment
|
Baseline (Week 0) and Weeks 4, 8, 16, and 24; blood samples collected at 0, 30, 60, 120, 180, and 240 minutes during each gastric emptying scintigraphy assessment
|
|
Changes from baseline in postprandial lipidomic profiles (Particle Diameter (nm))
Aikaikkuna: Baseline (Week 0) and Weeks 4, 8, 16, and 24; blood samples collected at 0, 30, 60, 120, 180, and 240 minutes during each gastric emptying scintigraphy assessment
|
Baseline (Week 0) and Weeks 4, 8, 16, and 24; blood samples collected at 0, 30, 60, 120, 180, and 240 minutes during each gastric emptying scintigraphy assessment
|
|
Changes from baseline in postprandial metabolomic profiles (Glycoprotein (μmol/L))
Aikaikkuna: Baseline (Week 0) and Weeks 4, 8, 16, and 24; blood samples collected at 0, 30, 60, 120, 180, and 240 minutes during each gastric emptying scintigraphy assessment
|
Baseline (Week 0) and Weeks 4, 8, 16, and 24; blood samples collected at 0, 30, 60, 120, 180, and 240 minutes during each gastric emptying scintigraphy assessment
|
|
Changes from baseline in postprandial metabolomic profiles (LMWM (mmol/L))
Aikaikkuna: Baseline (Week 0) and Weeks 4, 8, 16, and 24; blood samples collected at 0, 30, 60, 120, 180, and 240 minutes during each gastric emptying scintigraphy assessment
|
Baseline (Week 0) and Weeks 4, 8, 16, and 24; blood samples collected at 0, 30, 60, 120, 180, and 240 minutes during each gastric emptying scintigraphy assessment
|
|
Incidence of treatment-emergent adverse events including gastrointestinal symptoms
Aikaikkuna: From the first dose of tirzepatide through the end-of-study visit (Week 30).
|
From the first dose of tirzepatide through the end-of-study visit (Week 30).
|
|
Incidence of treatment-emergent adverse events including hypoglycemia
Aikaikkuna: From the first dose of tirzepatide through the end-of-study visit (Week 30).
|
From the first dose of tirzepatide through the end-of-study visit (Week 30).
|
|
Incidence of treatment-emergent adverse events including diabetic ketoacidosis
Aikaikkuna: From the first dose of tirzepatide through the end-of-study visit (Week 30).
|
From the first dose of tirzepatide through the end-of-study visit (Week 30).
|
|
Tolerability of tirzepatide during dose escalation, assessed by the frequency of dose reductions
Aikaikkuna: During the 24-week treatment period, through Week 24
|
During the 24-week treatment period, through Week 24
|
|
Tolerability of tirzepatide during dose escalation, assessed by the proportion of participants unable to reach the target dose of 15 mg
Aikaikkuna: During the 24-week treatment period, through Week 24
|
During the 24-week treatment period, through Week 24
|
Yhteistyökumppanit ja tutkijat
Sponsori
Sponsori
Yhteistyökumppanit
Yhteistyökumppanit
Opintojen ennätyspäivät
Opi tärkeimmät päivämäärät
Opiskelun aloitus (Todellinen)
Opiskelun aloitus
Ensisijainen valmistuminen (Arvioitu)
Ensisijainen valmistuminen
Opintojen valmistuminen (Arvioitu)
Opintojen valmistuminen
Opintoihin ilmoittautumispäivät
Ensimmäinen lähetetty
Ensimmäinen lähetetty
Ensimmäinen toimitettu, joka täytti QC-kriteerit
Ensimmäinen toimitettu, joka täytti QC-kriteerit
Ensimmäinen Lähetetty (Todellinen)
Ensimmäinen Lähetetty
Tutkimustietojen päivitykset
Viimeisin päivitys julkaistu (Todellinen)
Viimeisin päivitys julkaistu
Viimeisin lähetetty päivitys, joka täytti QC-kriteerit
Viimeisin lähetetty päivitys, joka täytti QC-kriteerit
Viimeksi vahvistettu
Viimeksi vahvistettu
Lisää tietoa
Tähän tutkimukseen liittyvät termit
Muita asiaankuuluvia MeSH-ehtoja
- Endokriinisen järjestelmän sairaudet
- Metaboliset sairaudet
- Autoimmuunisairaudet
- Immuunijärjestelmän sairaudet
- Glukoosiaineenvaihduntahäiriöt
- Diabetes mellitus
- Ravitsemukselliset ja aineenvaihduntataudit
- Diabetes mellitus, tyyppi 1
- Aminohapot, peptidit ja proteiinit
- Proteiinit
- Glukagonin kaltainen peptidi-1-reseptori
- Glukagonin kaltaiset peptidireseptorit
- Reseptorit, G-proteiiniin kytketty
- Reseptorit, solun pinta
- Kalvoproteiinit
- Reseptorit, maha -suolikanavan hormoni
- Reseptorit, peptidi
- Tirzepatide
Muut tutkimustunnusnumerot
Muut tutkimustunnusnumerot
- FAITH-T1D/1
- 2026-527062-72-00 (Ctis)
Lääke- ja laitetiedot, tutkimusasiakirjat
Tutkii yhdysvaltalaista FDA sääntelemää lääkevalmistetta
Tutkii yhdysvaltalaista FDA sääntelemää laitetuotetta
Yhdysvalloissa valmistettu ja sieltä viety tuote
Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .